The potential of tribody [(HER2)2xCD16] to enhance the cytotoxicity of these cells against allogeneic cancer cell lines and autologous primary OC cells was compared to the cytotoxic activity mediated by trastuzumab. Here, ERBB2 is linked to cancer.